Severe Gastrointestinal Mucositis Following Concurrent Palbociclib and Palliative Radiation Therapy.
Aged
Antineoplastic Agents
/ adverse effects
Biomarkers, Tumor
Breast Neoplasms
/ complications
Combined Modality Therapy
/ adverse effects
Endoscopy, Gastrointestinal
Female
Humans
Mucositis
/ diagnosis
Palliative Care
Piperazines
/ adverse effects
Protein Kinase Inhibitors
/ adverse effects
Pyridines
/ adverse effects
Radiotherapy Dosage
Radiotherapy, Adjuvant
/ adverse effects
Severity of Illness Index
Tomography, X-Ray Computed
Ibrance
Mucositis
chemoradiation
chemotherapy
palbociclib
palliative
radiation therapy
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
05
07
2020
revised:
22
07
2020
accepted:
23
07
2020
entrez:
4
9
2020
pubmed:
4
9
2020
medline:
20
9
2020
Statut:
ppublish
Résumé
Palbociclib is an FDA-approved cyclin-dependent kinase inhibitor for the treatment of advanced breast cancer. Limited information is available regarding the toxicity of palbociclib and concurrent radiation therapy. Herein, we report a case of esophageal toxicity in a patient treated with palbociclib and radiation therapy. A 63-year-old woman was treated with palbociclib followed by palliative radiation therapy. The patient presented three days after completing radiation therapy with severe odynophagia, and dysphagia and was found to have grade 2-3 esophageal ulcers. Palbociclib and radiation therapy was held on admission, and a resolution of her symptoms and improvement in her oral intake was noted at which time she was restarted on palbociclib with no further radiation treatment. Caution is advised when patients are undergoing concurrent palbociclib and even low-dose palliative radiation treatment. In these patients, providers should maintain a high index of suspicion for toxicities such as dermatitis or mucositis.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Palbociclib is an FDA-approved cyclin-dependent kinase inhibitor for the treatment of advanced breast cancer. Limited information is available regarding the toxicity of palbociclib and concurrent radiation therapy.
CASE REPORT
METHODS
Herein, we report a case of esophageal toxicity in a patient treated with palbociclib and radiation therapy. A 63-year-old woman was treated with palbociclib followed by palliative radiation therapy. The patient presented three days after completing radiation therapy with severe odynophagia, and dysphagia and was found to have grade 2-3 esophageal ulcers. Palbociclib and radiation therapy was held on admission, and a resolution of her symptoms and improvement in her oral intake was noted at which time she was restarted on palbociclib with no further radiation treatment.
CONCLUSION
CONCLUSIONS
Caution is advised when patients are undergoing concurrent palbociclib and even low-dose palliative radiation treatment. In these patients, providers should maintain a high index of suspicion for toxicities such as dermatitis or mucositis.
Identifiants
pubmed: 32878819
pii: 40/9/5291
doi: 10.21873/anticanres.14534
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers, Tumor
0
Piperazines
0
Protein Kinase Inhibitors
0
Pyridines
0
palbociclib
G9ZF61LE7G
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5291-5294Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.